Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Muir

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
JCI Insight|July 27, 2023
Human immune phenotyping reveals accelerated aging in type 1 diabetesMelanie R Shapiro, Xiaoru Dong, Daniel J Perry, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
Abdominal Radiology (New York)|April 28, 2025
Predictors of hepatocellular carcinoma in LR-M category lesions, a multi-institutional analysisMarybeth Nedrud, Tanya Wolfson, Brian Allen, et al.
Nature Genetics|July 13, 2004
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetesDehuang Guo, Manyu Li, Yan Zhang, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
The New England Journal of Medicine|September 28, 2022
Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes, Steven J Russell, Roy W Beck, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
JCI Insight|July 27, 2023
Human immune phenotyping reveals accelerated aging in type 1 diabetesMelanie R Shapiro, Xiaoru Dong, Daniel J Perry, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
Abdominal Radiology (New York)|April 28, 2025
Predictors of hepatocellular carcinoma in LR-M category lesions, a multi-institutional analysisMarybeth Nedrud, Tanya Wolfson, Brian Allen, et al.
Nature Genetics|July 13, 2004
A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetesDehuang Guo, Manyu Li, Yan Zhang, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
The New England Journal of Medicine|September 28, 2022
Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes, Steven J Russell, Roy W Beck, et al.
Pageof 7